Perez M I, Berger C L, Yamane Y, John L, Laroche L, Edelson R L
Department of Dermatology, Yale University, New Haven, Connecticut 06510-8059.
Transplantation. 1991 Jun;51(6):1283-9. doi: 10.1097/00007890-199106000-00026.
We have previously reported the capacity to produce donor-specific tolerance to alloantigens by intravenous exposure to pretreated antidonor T cells. The current study has refined this system by using congenic mice differing only at the H-2 major histocompatibility complex genetic loci. Twelve days after B10 mice received MHC-incompatible B10.D2 skin grafts, their splenocytes that included an expanded population of cells mediating rejection were treated with 100 ng/ml 8-methoxypsoralen (8-MOP) photoactivated by 1 J/cm2 of ultraviolet A prior to infusion into naive B10 recipients. Whereas 8-MOP itself is biologically inert, photoactivated 8-MOP crosslinks DNA by covalently binding to pyrimidine bases. Recipient B10 mice were tested for tolerance to B10.D2 alloantigens in mixed leukocyte culture (MLC), cytotoxicity (CTL), and to in vivo delayed type hypersensitivity assays and challenged with a fresh B10.D2 graft. In vivo, the DTH response of the pretreated B10 mice was specifically suppressed to the relevant alloantigen, correlating with retention of B10.D2 skin grafts for up to 22 days postengraftment without visual evidence of rejection, in comparison to control complete rejection of the skin graft in less than 12 days. In vitro, splenocytes from B10 recipients of pretreated syngeneic splenocytes containing large numbers of B10 anti-B10.D2 T cells proliferated less in MLC and generated lower cytotoxic T cell responses to B10.D2 alloantigens than did controls and suppressed the B10 MLC and CTL responses to B10.D2 alloantigen. These results reveal that, in a highly defined congenic transplantation system, infusions of photoinactivated effector cells resulted in selective inhibition of the in vivo responses that correlated with allograft rejection and permitted prolonged retention of histoincompatible skin grafts. This approach may have significant practical applicability for treatment of human disorders caused by aberrant T cells.
我们之前曾报道,通过静脉注射预处理的抗供体T细胞能够产生对同种异体抗原的供体特异性耐受性。当前的研究通过使用仅在H-2主要组织相容性复合体基因位点存在差异的同源小鼠对该系统进行了优化。在B10小鼠接受MHC不相容的B10.D2皮肤移植12天后,其包含介导排斥反应的扩增细胞群体的脾细胞,在注入未接触过抗原的B10受体之前,先用1 J/cm2的紫外线A光激活100 ng/ml的8-甲氧基补骨脂素(8-MOP)进行处理。虽然8-MOP本身无生物学活性,但光激活的8-MOP通过与嘧啶碱基共价结合使DNA交联。对受体B10小鼠进行混合淋巴细胞培养(MLC)、细胞毒性(CTL)检测,以评估其对B10.D2同种异体抗原的耐受性,并进行体内迟发型超敏反应检测,然后用新鲜的B10.D2移植物进行攻击。在体内,预处理的B10小鼠的迟发型超敏反应对相关同种异体抗原具有特异性抑制作用,这与B10.D2皮肤移植物在植入后长达22天的保留相关,肉眼未见排斥迹象,相比之下,对照皮肤移植物在不到12天内完全排斥。在体外,接受预处理的同基因脾细胞(含有大量B10抗B10.D2 T细胞)的B10受体的脾细胞在MLC中增殖较少,对B10.D2同种异体抗原产生的细胞毒性T细胞反应低于对照,并抑制了B10对B10.D2同种异体抗原的MLC和CTL反应。这些结果表明,在一个高度明确的同源移植系统中,注入光灭活的效应细胞导致与同种异体移植排斥相关的体内反应受到选择性抑制,并允许组织不相容的皮肤移植物长期保留。这种方法对于治疗由异常T细胞引起的人类疾病可能具有重要的实际应用价值。